Remission of ED appears more common than believed
August 1st 2006Atlanta-Remission of erectile dysfunction may be more common than has been previously believed, according to an analysis of data from the National Institutes of Health-supported Massachusetts Male Aging Study (MMAS). Findings from this analysis were reported at the AUA annual meeting here.
TRT appears prostate-safe in 6-month trial
August 1st 2006Atlanta-Testosterone replacement therapy (TRT) caused no adverse events in the prostate tissue of men with androgen decline of aging male (ADAM) syndrome after 6 months of treatment, according to a study presented at the AUA annual meeting here.
Drug lowers cholesterol in men receiving androgen deprivation therapy
July 20th 2006An oral drug under development for the treatment of multiple side effects of androgen deprivation therapy appears to lower total cholesterol levels, according to an interim analysis of phase III clinical trial results.
External catheter reduces risk of urinary tract infection
July 20th 2006An external or "condom" catheter appears to reduce the risk of urinary tract infections or death by 80 percent compared with an indwelling catheter, according to a randomized, controlled trial comparing the two types of catheters.
Once-daily overactive bladder drug shows promise
July 20th 2006The second of two phase III trials has shown that once-daily trospium chloride (Sanctura XR) reduces frequency of urination and the number of urge incontinence episodes in individuals with a once-daily formulation for the treatment of overactive bladder.
Radiation therapy does not increase rectal cancer risk
July 20th 2006Men who receive radiation therapy for prostate cancer are not at any appreciable increased risk of developing rectal cancer compared with those not given radiation therapy, according to a recently published study by Canadian researchers.
Fear, anecdotal evidence influence patients' decisions about prostate cancer treatment
July 6th 2006Prostate cancer patients make treatment decisions that are influenced by anecdote and misconception rather than clinical trial evidence, according to a study by researchers at the University of Colorado Health Sciences Center, Denver.
Urologist, not tumor characteristics, determines whether men receive androgen deprivation
July 6th 2006Among patients with locally advanced or metastatic prostate cancer, the decision about whether to receive androgen deprivation therapy depends primarily on who their urologist is, rather than the stage or grade of tumor or patient characteristics.
Test may help detect prostate cancer recurrence
July 6th 2006A new prognostic test may help determine whether a patient with prostate cancer will have a recurrence of the disease, even if surrounding lymph nodes initially appear negative for cancer, according to a study from the Keck School of Medicine at the University of Southern California, Los Angeles.
Fear, anecdotal evidence influence patients' decisions about prostate cancer treatment
July 6th 2006Prostate cancer patients make treatment decisions that are influenced by anecdote and misconception rather than clinical trial evidence, according to a study by researchers at the University of Colorado Health Sciences Center, Denver.
Obesity may be a predictor of prostate cancer recurrence
July 6th 2006Moderately and severely obese prostate cancer patients had a 99% greater risk of developing biochemical failure than other patients, according to the authors of a study from the University of Texas M.D. Anderson Cancer Center, Houston.
FDA issues guidelines for reprocessing ultrasound transducer assemblies
July 6th 2006After finding the lumen of a needle guide of an ultrasound transducer assembly soiled during patient safety rounds at a VA hospital, the FDA has issued a public health notification about the importance of properly cleaning and sterilizing reusable ultrasound biopsy transducer assemblies and guidelines for doing so.
Significant survival benefit seen in phase III study of prostate cancer agent
July 6th 2006Administration of sipuleucel-T (Provenge) in men with advanced androgen-independent prostate cancer shows a significant survival benefit and "a very favorable toxicity and safety profile," according to the authors of a double-blind, placebo-controlled, multicenter phase III study published recently in the Journal of Clinical Oncology (2006; 24:3089-94).
Botulinum toxin A shows efficacy in treating BPH
July 1st 2006Atlanta-Intraprostatic injection of botulinum toxin A (Botox) is a safe and effective treatment in patients with symptomatic BPH that results in improvements in symptoms and quality of life that may persist for up to 1 year, Chinese researchers reported at the AUA annual meeting here.
Posterior urethral injuries: How to evaluate and manage
July 1st 2006When men sustain pelvic fracture trauma, an associated posterior urethral injury will occur 4% to 10% of the time. This article discusses the evaluation and diagnosis of urethral injuries and outlines our group's approach to urethral reconstruction.
New prostate cancer assay aids critical diagnostic decisions
July 1st 2006Atlanta-A new prostate cancer test known as the PCA3 assay (Gen-Probe Inc., San Diego) remains a work in progress, but at this stage of development, it appears to offer significant utility in men with subtly elevated serum PSA (ie, ?2.5 ng/mL) but a negative initial biopsy.